{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:29:37Z","timestamp":1793276977236,"version":"4.5.0"},"reference-count":33,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Direct-acting antivirals (DAA) are effective in patients with hepatitis C virus (HCV) infection, but there is little information about real-world effectiveness in people living with human immunodeficiency virus (PLH). The aim of this study was to determinate the effectiveness of DAA to achieve sustained virologic response at week 12 post-treatment (SVR12) in PLH with HCV coinfection and in people with HCV-monoinfection. We conducted a prospective cohort. The full analysis set (FAS) included all subjects enrolled in the study; the modified analysis set (MAS) excluded cases with missing data to evaluate SVR12. A total of 278 people were included, 130 (46.7%) with HCV\/HIV-coinfection and 148 (53.2%) with HCV-monoinfection. In the HCV\/HIV-coinfection group, 82 (63%) received GLE\/PIB for 8 weeks, 45 (34.6%) received SOF\/VEL for 12 weeks, and 3 (2.3%) were treated with SOF\/VEL + RBV for 12 weeks. In the HCV-monoinfection group, 62 (41.8%) received GLE\/PIB for 8 weeks, 28 (18.9%) received SOF\/VEL for 12 weeks, and 58 (39.1%) participants were treated with SOF\/VEL + RBV for 12 weeks. In the FAS analysis, SVR12 was 81.6% in the HCV\/HIV-coinfection group and 86.4% in the HCV-monoinfection group (p = 0.128). In the MAS analysis, both groups achieved 100% of SVR12. In this cohort, the effectiveness of DAA to achieve SVR12 was similar between HCV\/HIV-coinfection and HCV-monoinfection cases, regardless of advanced liver disease with no differences between treatment regimens.<\/jats:p>","DOI":"10.3390\/v16111724","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T12:31:32Z","timestamp":1730377892000},"page":"1724","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effectiveness of Direct Antiviral Agents in People with HCV-Monoinfection Compared to HCV\/HIV Coinfection in a Real Life Setting"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8857-6921","authenticated-orcid":false,"given":"Cristina Guadalupe","family":"Rom\u00e1n L\u00f3pez","sequence":"first","affiliation":[{"name":"Internal Medicine Department, Hospital Regional No. 1 \u201cIgnacio Garc\u00eda Tellez\u201d, Instituto Mexicano del Seguro Social, M\u00e9rida 97150, Yucat\u00e1n, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4175-025X","authenticated-orcid":false,"given":"Salma","family":"Triana Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital de Infectologia \u201cLa Raza\u201d National Medical Center, Instituto Mexicano del Seguro Social, Mexico City 02990, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9659-746X","authenticated-orcid":false,"given":"Ana Luz","family":"Cano D\u00edaz","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital de Infectologia \u201cLa Raza\u201d National Medical Center, Instituto Mexicano del Seguro Social, Mexico City 02990, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dulce Daniela Flores","family":"Lopez","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital de Infectologia \u201cLa Raza\u201d National Medical Center, Instituto Mexicano del Seguro Social, Mexico City 02990, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3701-9894","authenticated-orcid":false,"given":"Jos\u00e9 Antonio","family":"Mata Mar\u00edn","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital de Infectologia \u201cLa Raza\u201d National Medical Center, Instituto Mexicano del Seguro Social, Mexico City 02990, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas Enrique","family":"Gayt\u00e1n Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Hospital de Infectologia \u201cLa Raza\u201d National Medical Center, Instituto Mexicano del Seguro Social, Mexico City 02990, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S1473-3099(15)00485-5","article-title":"Prevalence and burden of HCV co-infection in people living with HIV: A global systematic review and meta-analysis","volume":"16","author":"Platt","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S2468-1253(20)30303-4","article-title":"Prevalence and incidence of hepatitis C virus infection in men who have sex with men: A systematic review and meta-analysis","volume":"6","author":"Jin","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/cid\/ciz949","article-title":"Reinfection With the Hepatitis C Virus in Men Who Have Sex With Men After Successful Treatment With Direct-acting Antivirals in Germany: Current Incidence Rates, Compared With Rates During the Interferon Era","volume":"71","author":"Ingiliz","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/QAI.0000000000000528","article-title":"Risk factors for HCV acquisition among HIV-positive MSM in Belgium","volume":"68","author":"Apers","year":"2015","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Mata-Mar\u00edn, J.A., de Pablos-Leal, A.A., Mauss, S., Arroyo-Anduiza, C.I., Rodr\u00edguez-Evaristo, M.S., Uribe-Nogu\u00e9z, L.A., Berrospe-Silva, M.d.L., Lara-Casta\u00f1eda, J.C., P\u00e9rez-Barrag\u00e1n, E., and Gayt\u00e1n-Mart\u00ednez, J. (2022). Risk factors for HCV transmission in HIV-positive men who have sex with men in M\u00e9xico. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0269977"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2893.2005.00651.x","article-title":"Spontaneous viral clearance following acute hepatitis C infection: A systematic review of longitudinal studies","volume":"13","author":"Micallef","year":"2006","journal-title":"J. Viral Hepat."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/0956462416632428","article-title":"Prevalence and distribution of non-AIDS causes of death among HIV-infected individuals receiving antiretroviral therapy: A systematic review and meta-analysis","volume":"28","author":"Farahani","year":"2016","journal-title":"Int. J. STD AIDS"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1001\/archinte.166.15.1632","article-title":"Liver-Related Deaths in Persons Infected With the Human Immunodeficiency Virus","volume":"166","author":"Weber","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-8278(97)80001-3","article-title":"Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis","volume":"26","author":"Soto","year":"1997","journal-title":"J. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/S0140-6736(00)03232-3","article-title":"Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: The Swiss HIV Cohort Study","volume":"356","author":"Greub","year":"2000","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients","volume":"351","author":"Torriani","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1515\/jtim-2017-0007","article-title":"Direct Acting Anti-hepatitis C Virus Drugs: Clinical Pharmacology and Future Direction","volume":"5","author":"Geddawy","year":"2017","journal-title":"J. Transl. Intern. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/hep.24641","article-title":"An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases","volume":"54","author":"Ghany","year":"2011","journal-title":"Hepatology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e01620-17","DOI":"10.1128\/AAC.01620-17","article-title":"In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS3\/4A protease inhibitor glecaprevir","volume":"62","author":"Ng","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"809","DOI":"10.7326\/M15-1014","article-title":"Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients with Genotype 1 or 3 Hepatitis C Virus Infection","volume":"163","author":"Pianko","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"818","DOI":"10.7326\/M15-1000","article-title":"Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection. Annals of Internal Medicine","volume":"163","author":"Everson","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"ofaa055","DOI":"10.1093\/ofid\/ofaa055","article-title":"Real-world Effectiveness of Sofosbuvir\/Velpatasvir for Treatment of Chronic Hepatitis C in British Columbia, Canada: A Population-Based Cohort Study","volume":"7","author":"Wilton","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jhep.2020.01.025","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis","volume":"72","author":"Lampertico","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/jvh.13305","article-title":"Real-world effectiveness of glecaprevir\/pibrentasvir and ledipasvir\/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan","volume":"27","author":"Chiu","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Aghemo, A., Persico, M., D\u2019Ambrosio, R., Andreoni, M., Villa, E., Bhagat, A., Gallinaro, V., Gualberti, G., Merolla, R.C.D., and Gasbarrini, A. (2023). Safety and effectiveness of 8 weeks of Glecaprevir\/Pibrentasvir in challenging HCV patients: Italian data from the CREST study. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0280165"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/cid\/cix260","article-title":"Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study","volume":"65","author":"Wyles","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1093\/cid\/ciy220","article-title":"Efficacy and Safety of Glecaprevir\/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study","volume":"67","author":"Rockstroh","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1097\/QAD.0000000000001465","article-title":"Similar effectiveness of direct-acting antiviral against hepatitis C virus in patients with and without HIV infection","volume":"31","author":"Montes","year":"2017","journal-title":"AIDS"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Jose-Abrego, A., Trujillo-Trujillo, M.E., Laguna-Meraz, S., Roman, S., and Panduro, A. (2024). Epidemiology of Hepatitis C Virus in HIV Patients from West Mexico: Implications for Controlling and Preventing Viral Hepatitis. Pathogens, 13.","DOI":"10.3390\/pathogens13050360"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14218\/JCTH.2018.00007","article-title":"Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era","volume":"6","author":"Mathur","year":"2018","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1080\/09540121.2019.1645808","article-title":"Real life results of direct acting antiviral therapy for HCV infection in HIV-HCV-coinfected patients: Epi-Ter2 study","volume":"32","author":"Piekarska","year":"2020","journal-title":"AIDS Care"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/MEG.0000000000001759","article-title":"Utilization and effectiveness of elbasvir\/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: Results from the German Hepatitis C-Registry","volume":"33","author":"Hinrichsen","year":"2021","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3851\/IMP3353","article-title":"DAA-Based Treatment for HIV\u2013HCV-Coinfected Patients: Analysis of Factors of Sustained Virological Response in a Real-Life Study","volume":"25","author":"Alessio","year":"2019","journal-title":"Antivir. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Cotte, L., Pugliese, P., Valantin, M.A., Cuzin, L., Billaud, E., Duvivier, C., Naqvi, A., Cheret, A., Rey, D., and Pradat, P. (2016). Hepatitis C treatment initiation in HIV-HCV coinfected patients. BMC Infect. Dis., 16.","DOI":"10.1186\/s12879-016-1681-1"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1093\/jac\/dkad278","article-title":"Response to glecaprevir\/pibrentasvir in HIV\/HCV-coinfected patients in clinical practice","volume":"78","author":"Tellez","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/jvh.13844","article-title":"Efficacy and safety of pan-genotypic sofosbuvir and velpatasvir in patients with hepatitis C and HIV coinfection on dolutegravir-based antiretroviral therapy","volume":"30","author":"De","year":"2023","journal-title":"J. Viral Hepat."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jinf.2022.06.005","article-title":"High efficacy of glecaprevir\/pibrentasvir for HCV-infected individuals with active drug use","volume":"85","author":"Macias","year":"2022","journal-title":"J. Infect."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/11\/1724\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:25:59Z","timestamp":1760113559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/11\/1724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,31]]},"references-count":33,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["v16111724"],"URL":"https:\/\/doi.org\/10.3390\/v16111724","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,31]]}}}